|14th December 2020||David A Gonyer||23,954||Open or private sale||$2.94||$70,424.76|
|11th December 2020||David A Gonyer||48,046||Open or private sale||$2.90||$139,333.40|
|11th December 2020||Matthew J D'Onofrio||40,357||Open or private sale||$2.91||$117,438.87|
|10th December 2020||Matthew J D'Onofrio||5,643||Open or private sale||$2.95||$16,646.85|
|1st September 2020||David A Gonyer||20,238||Other acquisition or disposition||$1.05||$21,249.90|
|1st September 2020||Matthew J D'Onofrio||20,238||Other acquisition or disposition||$1.05||$21,249.90|
|1st September 2020||Marilyn R. Carlson||20,238||Other acquisition or disposition||$1.05||$21,249.90|
|2nd March 2020||Matthew J D'Onofrio||25,000||Grant/award etc.||$0.85||$21,250.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Evoke Pharma, Inc. develops Gimoti, with promotility and anti-emetic effects. Gimoti is for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.